medigraphic.com

2017, Número 1

<< Anterior

Rev Clin Esc Med 2017; 7 (1)


Aspectos básicos del bordaje Integral de las supervivientes de cáncer de mama

Landaverde D

Idioma: Español
Referencias bibliográficas: 38
Paginas: 11-18
Archivo PDF: 302.29 Kb.


FRAGMENTO

Debido a los avances en el manejo multidisciplinario del cáncer se ha incrementado la supervivencia de las pacientes tratadas por cáncer de mama con intención curativa, de la mano con este aumento, también es necesario conocer el abordaje idóneo de las mismas. Este artículo de revisión, pretende mostrar los aspectos relevantes y actualizados en el manejo de este creciente grupo, incluyendo recomendaciones en el tratamiento de comorbilidades asociadas, así como el beneficio potencial de los estilos de vida saludables.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Global Health Estimates, WHO 2013, http://www.who.int/cancer/detection/breastc ancer/en/index1.html

  2. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray, F. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet].Lyon, France: International Agency for Research on Cancer; 2013. Available from: http://globocan.iarc.fr, accessed on 10/08/2016.

  3. Coleman MP, et al. Cancer survival in five continents: a worldwidepopulation-based study (CONCORD). Lancet 2008; 9: 730- 756

  4. Justo N. et al. A Review of Breast Cancer Care and Outcomes in Latin America. The Oncologist 2013;18:248–256

  5. Dirven L, Van de Poll Franse LV, Aaronson NK, Reijneveld JC. Controversies in defining cancer survivorship. Lancet Oncol 2015; 16(6):610-2.

  6. National Coalition for Cancer Survivorship (NCCS). NCCS Mission,2016. http://www.cancercontrol.cancer.gov/aboutus/ our-mission. Accessed June 18, 2016

  7. National Cancer Institute (NCI) Office of Cancer Survivorship. Definitions, 2016. http://www.cancer.gov/publications/dictionar ies/cancer-terms?cdrid=445089. Accessed June18, 2016

  8. Oeffinger KC, McCabe MS. Models for delivering survivorship care. J Clin Oncol. 2006;24:5117-5124.

  9. Grunfeld E, Levine MN, Julian JA, et al. Randomized trial of long-term follow-up for early-stage breast cancer: a comparison of family physician versus specialist care. J Clin Oncol. 2006. 24:848-855.

  10. Grunfeld E, Mant D, Yudkin P, et al. Routine follow up of breast cancer in primary care: randomised trial. BMJ. 1996;313:665-669

  11. Runowicz CD, Leach CR, Henry NL, et al. American Cancer Society/American Society of Clinical Oncology breast cancer survivorship care guideline. J Clin Oncol. 2016; 34:611-35

  12. Salloum RG, Hornbrook MC, Fishman PA, et al. Adherence to surveillance care guidelines after breast and colorectal cancer treatment with curative intent. Cancer 2012; 118 (22):5644-51

  13. Keating NL, Landrum MB, Guadagnoli E, et al. Surveillance testing among survivors of early-stage breast cancer. J Clin Oncol 2007; 25:1074

  14. Wood ME, Vogel V, Ng A, et al. Second Malignant neoplasm: assessment and strategies for risk reduction. J Clin Oncolo 2012; 30:3734

  15. Curtis RE, Freedman DM, Ron E, et al. New Malignancies among Cancer Survivor: Seer Cancer Registries, 1973-2000. NIH Publication No. 05-5302 181-186. Washington, DC: National Cancer Institute;2006.

  16. Bodai BI, Tuso P. Breast Cancer Survivorship: A Comprehensive Review of Long-Term Medical Issues and Lifestyle Recommendations. Perm J. 2015 19(2):48- 79

  17. Ligibel JA, Alfano CM, Corneya KS, et al. American Society of Clinical Oncology position statement on obesity and cáncer. J Clin Oncol 2014 32:3568-3574

  18. Playdon MC, Bracken MD, Sanft TB. et al. Weight gain after breast cancer diagnosis and all-cause mortality: systematic review and meta-analysis. J Natl Cancer Inst. 2015; 107:djv275

  19. Holick CN, Newcomb PA, Trentham-Dietz A, et al. Physical activity and survival after diagnosis of invasive breast cancer. Cancer Epidemiol Biomarkers Prev 2008;17:379- 386

  20. Irwin ML, McTiernan A, Manson JE, et al. Physical activity and survival in postmenopausal women with breast cáncer: Results from the women’ health initiative. Cancer Prev Res (Phila). 2011;4:522-529

  21. Chlebowski RT, Blackburn GL, Thompson CA, et al. Dietary fat reduction and breast cancer outcome: Interim efficacy results from the Women’s Intervention Nutrition Study. J Natl Cancer Inst. 2006;98:1767- 1776

  22. Pierce JP, Natarajan L, Caan BJ, et al. Influence of a dietary very high in vegetables, fruit, and fiber and low in fat on prognosis following treatment for breast cáncer: the Women’s Healthy Eating and Living (WHEL) randomized trial. JAMA 2007;298:289-298

  23. Berube S, Lemieux J, Moore L, Maunsell E, Brisson J. Smoking at time of diagnosis and breast cancer-specific survival: New findings and systematic review with metaanalysis. Breast Cancer Res. 2014;16:R42

  24. Kwan ML, Chen WY, Flatt SW, et al. Postdianosis alcohol consumption and breast cancer prognosis in the after breast cancer pooling project. Cancer Epidemiol Biomarkers Prev. 2013;22:32-41

  25. Flatt SW, Thomson CA, Gold EB, et al. Low to moderate alcohol intake is not associated with increased mortality after breast cancer. Cancer Epidemiolol Biomarkers Prev 2010;19:681-688

  26. Gralow JR, Biermann JS, Farooki A, et al. NCCN Task Force Report: Bone Health in Carcer Care. J Natl Compr Canc Netw 2013 11:S1-S50; quiz S51 (suppl 3)

  27. Cosman F, de Beur SJ, LeBoff MS, et al. Clinician’s guide to prevention and treatment of osteoporosis. Osteroporos Int 2014;25:2359-2381

  28. Brufsky AM, Bosserman LD, Caradonna RR, et al. Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. Clin Breast Cancer. 2009;9:77-85

  29. Brufsky AM, Harker WG, Beck JT, et al. Final 5-year results of Z-FAST trial:adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole. Cancer. 2012;118: 1192- 1201.

  30. Coleman R, de Boer R, Eidtmann H, et al. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZOFAST study): final 60-month results. Ann Oncol. 2013;24:398-405.

  31. Eidtmann H, de Boer R, Bundred N, et al. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36- month results of the ZO-FAST Study. Ann Oncol. 2010;21: 2188-2194.

  32. Ellis GK, Bone HG, Chlebowski R, et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for non metastatic breast cancer. J Clin Oncol. 2008;26:4875-4882.

  33. Coleman R, Powles T, Paterson A, et al; Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet. 2015;386:1353-1361.

  34. Ganz PA, Hahn EE. Implementing a Survivorship Care Plan for Patients with Breast Cancer. J Clin Oncol 2008;26(5):759- 767

  35. Smith E, Pang H, Cirrincione C, et al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapyinduced painful peripheral neuropathy: A randomized clinical trial. JAMA 2013;309:1359-1367

  36. Kaplan M, Mahon S, Cope D, et al. Putting evidence into practice: Evidence-based interventions for hot flashes resulting from cancer therapies. Clin J Oncol Nurs 2011;15:149-157

  37. Burstein HJ, Prestrud AA, Seidfeld J, et al. American Society of Clinical Oncology clinical practice guideline: Update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J clin Oncol 2010 28:3784-3796

  38. Harrington CB, Hansen JA, Moskowitz M, et al. It’s not over when it’s over: long-term symptoms in cancer survivor-a systematic review. Int J Psychiatry Med 2010;40:163




2020     |     www.medigraphic.com